摘要
目的:探讨唾液酸结合免疫球蛋白样凝集素-15(Siglec-15)在唑来膦酸(ZOL)特异性γδT细胞的表达及与抗原提呈相关分子表达的关系。方法:流式细胞术检测ZOL刺激前及刺激后4 d、8 d、12 d和16 d,Siglec-15、CD80、CD86和人类白细胞抗原(HLA)-DR在健康对照(HC)和肺癌(LC)患者外周血中的表达及表达水平的相关性。结果:与ZOL刺激前相比,CD80^(+)、CD86^(+)和HLA-DR^(+)γδT细胞水平在HC和LC中均升高(P<0.05);随着ZOL刺激时间延长,Siglec-15在两组γδT细胞中的表达水平均出现先升后降趋势,在刺激后4 d,HC显著高于LC(P<0.05)。LC的Siglec-15^(+)γδT与CD80^(+)γδT细胞比例在刺激前及刺激后的4 d和8 d呈正相关(P<0.05)。结论:Siglec-15在ZOL特异性γδT细胞中的表达水平先升高后降低,表达水平的上调与CD80表达水平的升高有关。
Objective:To investigate expression characteristics of sialic acid-binding immunoglobulin-like lectin-15(Siglec-15on specificγδT cells stimulated by zoledronate(ZOL)and explore the associations of Siglec-15 with antigen-presenting molecules.Methods:Siglec-15,CD80,CD86 and HLA-DR expressions ofγδT cells in healthy controls(HC)and lung cancer(LC)patients were detected by flow cytometry at pretreatment and 4 d,8 d,12 d and 16 d after ZOL stimulation,correlation of Siglec-15^(+)γδT cells with CD80^(+),CD86^(+)and HLA-DR^(+)γδT cellswere analyzed.Results:Proportions of CD80^(+),CD86^(+)and HLA-DR^(+)γδT cells in HC and LC were significantly increased compared with pretreatment(P<0.05).Levels ofγδT cells expressing Siglec-15 increased firstly and then decreased over the ZOL stimulation in both HC and LC groups(P<0.05),and proportion of Siglec-15^(+)γδT cells in HC group was significantly higher than that of LC on the 4th day after ZOL stimulation(P<0.05).Ratios of Siglec-15^(+)γδT cells in LC were positively correlated with CD80^(+)γδT cells at pretreatment(P<0.05),4 d and 8 d after ZOL stimulation(P<0.05).Conclusion:Expression levels of Siglec-15 in ZOL-specificγδT cells increase initially and then decrease,and the up-regulated expression of Siglec-15 is related to the increase of CD80 expression.
作者
游红琴
黄正华
朱会芳
韩露
李林霖
高全立
YOU Hongqin;HUANG Zhenghua;ZHU Huifang;HAN Lu;LI Linlin;GAO Quanli(The Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Zhengzhou 450008,China)
出处
《中国免疫学杂志》
CAS
CSCD
北大核心
2022年第20期2438-2442,共5页
Chinese Journal of Immunology
基金
河南省医学科技攻关计划(联合共建)项目(LHGJ20190645)
河南省重点研发与推广专项(科技攻关)项目(212102310120)。